- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05169931
Clinical Efficacy of Amniotic Membrane Extract Eye Drops in Dry Eye Treatment
November 7, 2022 updated by: Saba K. Al-Hashimi, MD, University of California, Los Angeles
This prospective longitudinal study aims at evaluating the clinical efficacy of human amniotic fluid extract eye drops in the treatment of dry eye disease.
25 patients who are diagnosed with dry eye disease as defined by our criteria will be recruited from the cornea and dry eye clinic at Stein Eye Institute, UCLA.
Pre-treatment baseline evaluations, 6 weeks, 12 weeks, and 24 weeks post treatment assessments will be performed by the principle investigator and co-investigator.
All tests are considered non-invasive and are within the standard of practice in the evaluation for dry eye disease: (1) Ocular Surface Disease Index Questionnaire (OSDI); (2) Non-contact Tear Break-up Time (NITBUT); (3) Shirmer's test without anesthesia; (4) Ocular Surface Staining with Fluorescein and Lissamine green.
Result of each test will be compared and analyzed to provide evidence of treatment efficacy.
Treatment will be initiated for 12 weeks at a self-administered dose of one drop in both eyes two times per day.
A follow-up of the study will be observed at the 24th week from the first day of treatment.
All side effects and adverse events will be carefully observed and documented.
Patients will be able to discontinue using the medication if they are not tolerating any side effects.
Study Overview
Study Type
Interventional
Phase
- Early Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults (18 years or older)
Presence of dry eye disease as defined as:
- Ocular Suface Disease Index (OSDI) score >13 AND EITHER i: Non-contact tear break-up time (NITBUT) < 10 seconds OR ii: Ocular Surface Staining (OSS) score > 1 in either eye
Exclusion Criteria:
Systemic diseases or comorbidities that may cause severe or secondary dry eye:
- Previous diagnosis of lymphoma, hepatitis C, HIV/AIDS, sarcoidosis, or amyloidosis that involves lacrimal glands
- Previous diagnosis of graft versus host disease (e.g., after bone marrow transplantation treatment for cancer) or cicatrizing conjunctivitis (e.g., Steven Johnson Syndrome, mucous membrane pemphigoid, trachoma)
- Anatomical or neurological lid closure problems (e.g., Bell's palsy, cicatricial ectropion, Alzheimer's disease, Parkinson's disease) 4
- Any history of chemotherapy, head or neck radiation treatment, or radioactive iodine treatment within 1 year prior to enrollment
- High dose oral or systemic steroids (equivalent to or greater than 5 mg prednisone) or immunosuppressive medication within 30 days prior to enrollment. Patients who are on stable dosing are eligible.
- Frequent or recent change in systemic medication regimen (e.g., diuretics, beta blockers, immunosuppressive medications, antidepressants that are known to interfere with dry eye) within 3 months prior to enrollment that may influence the ocular surface.
Other ocular surface diseases or surgical history that may cause severe or secondary dry eye:
- History of corneal dystrophy that in the opinion of the investigator is significantly affecting the ocular surface (e.g., significant anterior basement membrane dystrophy, Fuch's dystrophy with significant corneal edema and bullae, neurotrophic keratoconjunctivitis or corneal/conjunctival scarring including herpes simplex virus [HSV] or varicella zoster virus [VZV] keratitis)
- Any history of surgery for glaucoma (e.g., trabeculectomy, tube shunt)
- Corneal refractive surgery (e.g., laser in-situ keratomileusis [LASIK], photorefractive keratectomy [PRK], Intacs) within 6 months prior to enrollment
- Cataract, eyelid surgery, or retinal surgery (in operating room) within 6 months prior to enrollment
Use of treatments that may interfere with the ocular surface and/or treatment efficacy:
- Any in-office dry eye procedures (e.g., Intense Pulsed Light [IPL], LipiFlow®, nasolacrimal duct probing) within 30 days prior to enrollment
- Use of anti-glaucoma drops, topical antihistamines drops, or topical steroid drops within 7 days prior to enrollment
- Use of contact lenses. Patients willing to discontinue usage for 48 hours prior to each study visit will be eligible.
- Use of scleral lens, such as the prosthetic replacement of the ocular surface ecosystem (PROSE) lens
- Current use of topical lifitegrast (Xiidra®), topical cyclosporine (Restasis®), topical tacrolimus, or topical pimecrolimus. Patients willing to discontinue their due to insufficient benefit will be eligible.
Other important exclusion criteria:
- Current smoker (within 1 year prior to enrollment).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Study group
Treatment group to receive study drops (RegenerEyes) twice daily for 12 weeks
|
Biologic eye drop
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocular Surface Disease Index
Time Frame: 12 weeks
|
Symptom Questionnaire
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ocular Surface Staining Score
Time Frame: 12 weeks
|
12 weeks
|
|
Schirmer Score
Time Frame: 12 weeks
|
Schirmer score after 5 minutes with anesthesia
|
12 weeks
|
Non-contact Tear Break-up Time
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Saba Al-Hashimi, M.D, University of California, Los Angeles
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- O'Neil EC, Henderson M, Massaro-Giordano M, Bunya VY. Advances in dry eye disease treatment. Curr Opin Ophthalmol. 2019 May;30(3):166-178. doi: 10.1097/ICU.0000000000000569.
- Murri MS, Moshirfar M, Birdsong OC, Ronquillo YC, Ding Y, Hoopes PC. Amniotic membrane extract and eye drops: a review of literature and clinical application. Clin Ophthalmol. 2018 Jun 18;12:1105-1112. doi: 10.2147/OPTH.S165553. eCollection 2018.
- Quinto GG, Camacho W, Castro-Combs J, Li L, Martins SA, Wittmann P, Campos M, Behrens A. Effects of topical human amniotic fluid and human serum in a mouse model of keratoconjunctivitis sicca. Cornea. 2012 Apr;31(4):424-30. doi: 10.1097/ICO.0b013e31823f0a64.
- Yeu E, Goldberg DF, Mah FS, Beckman KA, Luchs JI, Solomon JD, White DE, Gupta PK. Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease. Clin Ophthalmol. 2019 May 27;13:887-894. doi: 10.2147/OPTH.S203510. eCollection 2019.
- Chen M, Chang CK, Lin SY, Chen M. A Pilot Study of the Short Term Effectiveness and Safety of Amniotic Fluid in Severe Dry Eye Disease. Med Hypothesis Discov Innov Ophthalmol. 2019 Summer;8(2):81-84.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
January 1, 2022
Primary Completion (ANTICIPATED)
April 1, 2022
Study Completion (ANTICIPATED)
May 1, 2022
Study Registration Dates
First Submitted
December 14, 2021
First Submitted That Met QC Criteria
December 14, 2021
First Posted (ACTUAL)
December 27, 2021
Study Record Updates
Last Update Posted (ACTUAL)
November 10, 2022
Last Update Submitted That Met QC Criteria
November 7, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-001915
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dry Eyes Chronic
-
Clínica de Oftalmología de Cali S.ACompletedMeibomian Gland Dysfunction | Eyes Dry ChronicColombia
-
Occyo GmbHUniversity Clinic for Ophthalmology and Optometry- SalzburgCompletedLimbal Stem-cell Deficiency | Cornea Disease | Eyes Dry Chronic | Chronic Conjunctivitis of Both Eyes | Eye Lesion | Eye Disease; Cataract | Eyes Dry Feeling of | Cornea Inflamed | Cornea; Injury, Abrasion | Cornea InfectionAustria
-
Laboratorios Sophia S.A de C.V.Not yet recruitingDry Eye | Dry Eye Syndromes | Dry Eyes Chronic
-
Singapore National Eye CentreCompleted
-
Singapore National Eye CentreCompleted
-
University of MichiganEversight Michigan/Michigan Eye BankCompleted
-
Weill Medical College of Cornell UniversityNovartisWithdrawnDry Eye | Dry Eye Syndromes | Dry Eyes ChronicUnited States
-
Singapore National Eye CentreCompleted
-
National University of MalaysiaCompleted